In the optimistic scenario, patients kept declining, but the reason for considering this optimistic is that we found it unlikely that amyloid clearance could result in substantially increasing benefit after the end of the trial periods in symptomatic AD patients, given the existence of pathological tau and copathologies such as vascular disease, Lewy bodies, and TAR DNA‐binding protein 43  aggregates in the vast majority of these patients.24 This evidence concerns the gene MAPT and Alzheimer disease.